Absolute Bioavailability of Vemurafenib in Patients With BRAF V600 Mutation–Positive Malignancies-Reference-Cited by-同舟云学术

Absolute Bioavailability of Vemurafenib in Patients With BRAF V600 Mutation–Positive Malignancies

Published:2020-02-21 Issue:4 Volume:9 Page:496-504
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Zhang Weijiang¹,Colburn Dawn²,Simmons Brian²,Papai Zsuzsanna³,Bertran Enric⁴,Schadt Simone⁴,Husser Christophe⁴,Forbes Harper⁵,Roethlisberger Dieter⁴,Hartung Thomas⁴

Affiliation:

1. Roche Innovation Center New York New York New York USA

2. Genentech, Inc South San Francisco California USA

3. PRA Magyarország Kft Fázis I‐es Klinikai Farmakológiai Vizsgálóhely Budapest Hungary

4. Roche Innovation Center Basel Basel Switzerland

5. Hoffmann‐La Roche Ltd Mississauga Ontario Canada

Funder

F. Hoffmann-La Roche, Ltd.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.773

Reference21 articles.

1. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

2. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

3. Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis

4. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

5. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Understanding and Management of Erdheim-Chester Disease;Life Sciences;2024-07

2. The application of Phase 0 and microtracer approaches in early clinical development: past, present, and future;Frontiers in Pharmacology;2024-03-18

3. Current Trends in API Co-Processing: Spherical Crystallization and Co-Precipitation Techniques;Journal of Pharmaceutical Sciences;2023-08

4. Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug–Drug Interaction and Improving Clinical Practice;Clinical Pharmacokinetics;2023-01

5. Erdheim-Chester Disease: a comprehensive review from the ophthalmologic perspective;Survey of Ophthalmology;2021-05